Form 4: CorMedix Director Sells 10,000 Shares

CorMedix Inc. Director Janet Dillione sold 10,000 shares of common stock at a weighted average price of $6.88 per share.

Summary

• Janet Dillione, a Director of CorMedix Inc. (CRMD), sold 10,000 shares of common stock.
• The transaction occurred on January 21, 2026, at a weighted average price of $6.88 per share.
• Individual trades for the sale ranged from $6.85 to $6.90 per share.
• Following this transaction, Dillione directly beneficially owns 38,473 shares of CorMedix common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was indicated by checking the relevant box on the Form 4.
• A Power of Attorney was granted by Janet Dillione to Beth Zelnick Kaufman on January 14, 2026, authorizing her to prepare and file SEC forms on Dillione's behalf.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even if pre-planned under a 10b5-1 plan, can be viewed with slight caution by investors as it reduces insider ownership. However, the pre-planned nature mitigates the immediate negative impact.

Positives

• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-planned sale rather than an immediate reaction to new information, which can mitigate negative investor perception.

Negatives

• A director sold a significant number of shares (10,000 shares), which could be perceived negatively by some investors as it reduces insider ownership.

Risks

• Potential negative investor perception due to a director selling shares, even if executed under a pre-planned Rule 10b5-1 arrangement.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it is a report of past insider transactions.

Management Comments

• The reporting person undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends. Insider selling can sometimes be interpreted by the market as a signal, but without further context, it is difficult to draw conclusions about industry trends.

Comparison to Industry Standards

• This filing is a standard insider trading report (Form 4) and does not contain information that allows for a direct comparison to industry-specific operational or financial benchmarks. Insider selling is a common occurrence across all industries, and its significance is often evaluated in the context of the company's specific performance and other insider activity.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially influencing market sentiment regarding the company's stock.

Next Steps

• No specific future actions or milestones are mentioned in this filing beyond the ongoing requirement for the director to file Forms 3, 4, 5, and 144 as applicable.

Key Dates

Recommendation

The filing reports a director's sale of 10,000 shares, executed under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, a pre-planned sale mitigates immediate concerns about new adverse information. Without additional company-specific news or financial performance data, this transaction alone does not warrant a 'buy' or 'sell' recommendation, suggesting a 'hold' position while monitoring further developments.

Keywords

CorMedix Inc., CRMD, Insider Trading, Form 4, Stock Sale, Janet Dillione, Director, 10b5-1 Plan